AstraZeneca's antibody cocktail for COVID-19, now called Evusheld, has become the first drug in the class to be authorised for prevention of infection by the US FDA.
Preliminary study results from South Africa have suggested that antibodies stimulated by Pfizer and BioNTech's Comirnaty are less effective against the new COVID-19 variant Omicron.
The European Commission has moved swiftly to grant full approval to Roche's Actemra/RoActemra as a treatment for severe COVID-19, clearing the drug within 24 hours of a recommendation from
The Omicron variant could supersede other strains of COVID-19 within the next few weeks to become dominant in the UK, according to an infectious diseases expert.
A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body's T-cell immunity against the disease.
The UK government has placed a 114 million-dose order with Pfizer/BioNTech and Moderna – sufficient to provide two doses to every person in Britain – in a bid to future-proof against COVID-